Clinical Trials
7 trialsNCT07504588 2026-06-03
Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT06028932 2026-03-05
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
Phase 2 Active not recruiting
NCT04251416 2026-02-17
A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
Yale University
Phase 2 Active not recruiting
NCT05838521 2026-02-06
A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer
Yale University
Phase 2 Recruiting
NCT06486441 2026-01-15
ASCENT-GYN-01
Gilead Sciences
Phase 3 Active not recruiting
NCT06040970 2025-12-02
Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer
Icahn School of Medicine at Mount Sinai
Phase 1/2 Recruiting
NCT05867251 2025-11-19
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Phase 1/2 Recruiting